Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Bixby Wealth Solutions on Strategic Minority Investment in F.L.PutnamJuly 31, 2026Sidley Represents BOX Exchange in US$2.3 Billion Strategic Combination With MEMXJuly 30, 2026Alignment Is Not Control: Court of Chancery Dismisses the KnowBe4 ChallengeJuly 29, 2026Sidley Represents Tiptree Inc. in Its Acquisition of Universal Shield Insurance GroupJuly 29, 2026When AI Changes the Deal: Rethinking Risk, Milestones, and Timing in Life Sciences M&AJuly 29, 2026Sidley Advises Kinderhook Industries in Investment in American AeroJuly 27, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory